01/28/2015 - 4:34pm

"During one of the sessions at the 2008 NACDS Regional Chain Conference, we projected onto the video screen some images of advertisements that NACDS was beginning to use in the Washington, D.C. area. Looking back, one of the things that I remember most was the boldness and strategic focus of the tagline: 'Pharmacies. The face of neighborhood healthcare.' With the 2015 edition of this meeting just days away, it is striking how far we have come!" writes NACDS president and CEO Steve Anderson in his latest blog post. 

01/28/2015 - 1:53pm

The House Energy and Commerce Committee on Tuesday released a discussion document in the 21st Century Cures initiative.

01/27/2015 - 1:43pm

Flu incidence is not ony predominant but still on the rise across Oklahoma, Arkansas and Texas.

01/27/2015 - 11:07am

Symplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension. 

01/27/2015 - 11:01am

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

01/27/2015 - 10:11am

Health and Human Services Secretary Sylvia Burwell announced goals and a timeline to move the Medicare program toward paying providers based on the quality of care they give patients.

 

01/26/2015 - 2:12pm

The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.

 

01/26/2015 - 2:09pm

The Food and Drug Administration last week approved Natpara (parathyroid horomone), which is indicated to control low blood calcium levels in patients who have hypoparathyroidism.

 

01/26/2015 - 10:59am

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.